IRB #

IRB00008569

Title

A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer

Principal Investigator

Tomasz Beer

Study Purpose

The purpose of this study is to learn if the study drug (custirsen), when given with cabazitaxel and prednisone, is better than cabazitaxel and prednisone alone at increasing survival in patients with metastatic, castrate resistant prostate cancer. The study will also see if custirsen is safe when given with cabazitaxel and prednisone.

Medical Condition(s)

Metastatic Castrate Resistant Prostate Cancer

Eligibility Criteria

*Metastatic prostate cancer
*Previous treatment with Docetaxel

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Up to 7.5 months on treatment

Minors Included

No

Contact

Rachel Slottke (503) 494-6117

Sponsor

OncoGeneX Technologies Inc.

Recruitment End

Compensation Provided

No